Details of the Drug Combination

General Information of Drug Combination (ID: DCHJHEU)

Drug Combination Name
ABIRATERONE BIO-300
Indication
Disease Entry Status REF
High grade ovarian serous adenocarcinoma Investigative [1]
Component Drugs ABIRATERONE   DM8V75C BIO-300   DMJ7NVI
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: OVCAR-5
Zero Interaction Potency (ZIP) Score: 6.46
Bliss Independence Score: 6.23
Loewe Additivity Score: 0.03
LHighest Single Agent (HSA) Score: 7.54

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of ABIRATERONE
Disease Entry ICD 11 Status REF
Prostate cancer 2C82.0 Approved [2]
ABIRATERONE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Steroid 17-alpha-monooxygenase (S17AH) TTRA5BZ CP17A_HUMAN Modulator [5]
------------------------------------------------------------------------------------
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Rheumatoid arthritis FA20 Phase 1 [4]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCJ378D MOLT-4 Investigative [6]
Chronic myelogenous leukemia DCY4M3E K-562 Investigative [6]
Clear cell renal cell carcinoma DCY6Z1X TK-10 Investigative [6]
Glioma DCDBPMK SF-539 Investigative [6]
Plasma cell myeloma DC4LKRS RPMI-8226 Investigative [6]
Renal cell carcinoma DCXAJAQ UO-31 Investigative [6]
Breast adenocarcinoma DCGMH4G MDA-MB-468 Investigative [7]
Carcinoma DCVER8D RXF 393 Investigative [7]
Carcinoma DCZ7F0H MCF7 Investigative [7]
Colon carcinoma DCW9574 KM12 Investigative [7]
Adenocarcinoma DCOJUXG OVCAR3 Investigative [1]
Adenocarcinoma DCUQOL1 NCIH23 Investigative [1]
Adenocarcinoma DCEUISK A549 Investigative [1]
Adenocarcinoma DC4ROT5 SW-620 Investigative [1]
Adenocarcinoma DCH4V7Z HCT116 Investigative [1]
Adenocarcinoma DCX2JO5 HCC-2998 Investigative [1]
Adenocarcinoma DCDLZLP HCT-15 Investigative [1]
Adenocarcinoma DCPKYQB HT29 Investigative [1]
Amelanotic melanoma DCBGA2Q M14 Investigative [1]
Amelanotic melanoma DCBPDWP MDA-MB-435 Investigative [1]
Cutaneous melanoma DCJDGFG SK-MEL-28 Investigative [1]
High grade ovarian serous adenocarcinoma DCT80CC OVCAR-8 Investigative [1]
Lung adenocarcinoma DCCMCPF MDA-MB-231 Investigative [1]
Lung adenocarcinoma DCSDS32 HOP-62 Investigative [1]
Lung adenocarcinoma DC72CT0 NCI-H522 Investigative [1]
Melanoma DCHOEY1 MALME-3M Investigative [1]
Pleural epithelioid mesothelioma DCWA9WR NCI-H226 Investigative [1]
Prostate carcinoma DCFFW46 PC-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6745).
3 Clinical pipeline report, company report or official report of Humanetics.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
6 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
7 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165